The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 6, Pages 1918
Publisher
MDPI AG
Online
2020-06-19
DOI
10.3390/jcm9061918
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data
- (2020) Benoît Colinet et al. ACTA CLINICA BELGICA
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
- (2019) Sabrina Baltschukat et al. CLINICAL CANCER RESEARCH
- Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor
- (2019) Yi Gu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
- (2019) Oliver Gautschi et al. Journal of Thoracic Oncology
- A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
- (2019) Giorgio Scagliotti et al. Journal of Thoracic Oncology
- MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
- (2018) Henning Reis et al. Clinical Lung Cancer
- C-MET inhibitors for advanced non-small cell lung cancer
- (2018) Giulia Pasquini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR- Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
- (2018) Giorgio V. Scagliotti et al. Journal of Thoracic Oncology
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
- (2018) David E. Gerber et al. LUNG CANCER
- PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers
- (2018) J K Sabari et al. ANNALS OF ONCOLOGY
- Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
- (2018) S Gadgeel et al. ANNALS OF ONCOLOGY
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma
- (2018) Beth A. Hellerstedt et al. Clinical Lung Cancer
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
- (2017) Thanyanan Reungwetwattana et al. LUNG CANCER
- MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
- (2017) Ravi Salgia MOLECULAR CANCER THERAPEUTICS
- Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
- (2017) Kentaro Inamura Frontiers in Oncology
- Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer
- (2016) Kelong Han et al. AAPS Journal
- Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
- (2016) Joel W Neal et al. LANCET ONCOLOGY
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial
- (2016) Oscar Arrieta et al. Targeted Oncology
- Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer
- (2015) Robert M. Sargis et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
- (2014) Theodore R. Johnson et al. XENOBIOTICA
- Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
- (2014) Patrick Ma et al. Cancer Management and Research
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
- (2013) J. Jean Cui JOURNAL OF MEDICINAL CHEMISTRY
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search